MicroPort Scientific Corporation (MCRPF) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
$'dan işlem gören MicroPort Scientific Corporation (MCRPF), 0 değerindeki bir Healthcare şirketidir. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 59/100 puan alıyor.
Son analiz: 17 Mar 2026MicroPort Scientific Corporation (MCRPF) Sağlık ve Boru Hattı Genel Bakışı
MicroPort Scientific Corporation is a global medical device company specializing in cardiovascular, orthopedic, and surgical robotic solutions. With a focus on innovation and international expansion, MicroPort serves diverse markets, including China, North America, and Europe, positioning itself as a key player in the medical device industry.
Yatırım Tezi
MicroPort Scientific Corporation presents a mixed investment thesis. The company's diverse product portfolio across multiple high-growth medical device segments, including surgical robotics and cardiovascular devices, offers significant growth potential. Expansion into international markets, particularly in emerging economies, could drive revenue growth. However, the company's negative profit margin of -16.1% and negative P/E ratio of -12.91 raise concerns about profitability. Successful commercialization of its surgical robot technologies and continued innovation in its core cardiovascular and orthopedic segments are key to future success. Investors should closely monitor the company's ability to improve profitability and manage its operating expenses.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market Cap of $2.90B reflects its position as a significant player in the medical device market.
- Gross Margin of 54.1% indicates strong pricing power and efficient manufacturing processes.
- Operating in multiple segments including Cardiovascular Devices, Orthopedics Devices, and Surgical Robot Business, diversifying its revenue streams.
- Global presence in the People's Republic of China, North America, Europe, other Asian countries, and South America.
- Beta of 0.39 suggests lower volatility compared to the overall market.
Rakipler & Benzerleri
Güçlü Yönler
- Diverse product portfolio across multiple medical device segments.
- Strong presence in China and other emerging markets.
- Innovative surgical robotics platform.
- Established brand reputation and relationships with healthcare providers.
Zayıflıklar
- Negative profit margin and P/E ratio.
- High operating expenses.
- Dependence on regulatory approvals for new products.
- Exposure to currency fluctuations.
Katalizörler
- Upcoming: Regulatory approvals for new medical devices in key markets.
- Upcoming: Commercialization of surgical robots in China and other emerging markets.
- Ongoing: Expansion of distribution network and partnerships with healthcare providers.
- Ongoing: Continued innovation in cardiovascular and orthopedic devices.
- Ongoing: Strategic acquisitions to expand product portfolio and geographic reach.
Riskler
- Potential: Intense competition from established medical device companies.
- Potential: Stringent regulatory requirements and product recalls.
- Potential: Pricing pressures from healthcare providers and payers.
- Ongoing: Negative profit margin and high operating expenses.
- Ongoing: Dependence on regulatory approvals for new products.
Büyüme Fırsatları
- Expansion of Surgical Robotics Business: MicroPort's Surgical Robot Business segment represents a significant growth opportunity. The global surgical robotics market is projected to reach $14.4 billion by 2026, growing at a CAGR of 12.7%. Successful commercialization of its surgical robots, particularly in China and other emerging markets, could drive substantial revenue growth. The company's focus on developing cost-effective and versatile robotic platforms could provide a competitive advantage.
- Penetration of Emerging Markets: Expanding its presence in emerging markets, particularly in Asia and South America, offers significant growth potential. These markets are experiencing rapid growth in healthcare expenditure and increasing demand for advanced medical devices. MicroPort's established presence in China provides a strong foundation for expanding into other Asian markets. Tailoring its products and services to meet the specific needs of these markets could drive revenue growth.
- Innovation in Cardiovascular Devices: Continued innovation in its Cardiovascular Devices segment, including the development of next-generation stents and delivery systems, is crucial for maintaining its competitive position. The global cardiovascular devices market is projected to reach $60 billion by 2026. Focusing on developing innovative solutions for complex coronary artery diseases and expanding its product portfolio to include new therapeutic areas could drive growth.
- Growth in Orthopedic Devices: The Orthopedics Devices segment offers growth opportunities through the development of advanced implants and surgical techniques. The global orthopedic devices market is projected to reach $55 billion by 2026. Focusing on developing personalized implants and minimally invasive surgical solutions could drive growth in this segment. Expanding its distribution network and strengthening its relationships with orthopedic surgeons are also important for success.
- Strategic Acquisitions and Partnerships: Pursuing strategic acquisitions and partnerships to expand its product portfolio and geographic reach represents another growth opportunity. Acquiring companies with complementary technologies or established market positions could accelerate its growth and enhance its competitive advantage. Partnering with leading research institutions and healthcare providers could also drive innovation and improve its market access.
Fırsatlar
- Expansion of surgical robotics business.
- Penetration of emerging markets.
- Innovation in cardiovascular and orthopedic devices.
- Strategic acquisitions and partnerships.
Tehditler
- Intense competition from established medical device companies.
- Stringent regulatory requirements and product recalls.
- Pricing pressures from healthcare providers and payers.
- Economic slowdown in key markets.
Rekabet Avantajları
- Strong brand reputation in the medical device industry.
- Extensive product portfolio across multiple therapeutic areas.
- Established presence in China and other emerging markets.
- Proprietary technologies and intellectual property.
- Strong relationships with key opinion leaders and healthcare providers.
MCRPF Hakkında
Founded in 1998 and headquartered in Shanghai, China, MicroPort Scientific Corporation has evolved into a prominent global medical device company. The company's initial focus was on developing and manufacturing cardiovascular devices, specifically coronary stents, to address the growing need for advanced cardiac care in China. Over the years, MicroPort expanded its product portfolio through strategic acquisitions and internal research and development, venturing into orthopedics, cardiac rhythm management, endovascular solutions, neurovascular devices, heart valve technologies, surgical robots, and surgical devices. Today, MicroPort operates through several key segments. The Cardiovascular Devices segment offers coronary stents and related delivery systems. The Orthopedics Devices segment provides reconstructive joints and spine implants. The Cardiac Rhythm Management Business segment offers defibrillators and pacemakers. The Endovascular and Peripheral Vascular Devices segment provides products for aortic and peripheral vascular diseases. The Neurovascular Devices segment offers neurovascular therapeutic devices. The Heart Valve Business segment provides transcatheter aortic valves. The Surgical Robot Business segment designs surgical robots. The Surgical Devices segment researches and sells surgical devices. MicroPort distributes its products across China, North America, Europe, and other international markets.
Ne Yaparlar
- Manufactures and distributes medical devices globally.
- Offers products for cardiovascular diseases, including coronary stents and delivery systems.
- Provides orthopedic implants for reconstructive joint surgery and spine procedures.
- Develops and markets cardiac rhythm management devices, such as defibrillators and pacemakers.
- Offers endovascular and peripheral vascular devices for treating aortic and vascular diseases.
- Provides neurovascular devices for treating neurovascular diseases.
- Develops and commercializes surgical robots for various surgical procedures.
- Manufactures and sells surgical devices.
İş Modeli
- Develops, manufactures, and markets a broad range of medical devices.
- Generates revenue through the sale of its products to hospitals, clinics, and healthcare providers.
- Invests in research and development to innovate and expand its product portfolio.
- Distributes its products through a network of sales representatives and distributors.
- Focuses on international expansion to drive revenue growth.
Sektör Bağlamı
The medical device industry is characterized by continuous innovation, stringent regulatory requirements, and increasing demand driven by an aging global population and rising healthcare expenditure. MicroPort Scientific Corporation operates in a competitive landscape that includes major players like Medtronic, Johnson & Johnson, and Stryker, as well as specialized competitors in each of its segments. The industry is experiencing growth in minimally invasive surgery, robotic surgery, and personalized medicine, creating opportunities for MicroPort to leverage its R&D capabilities and expand its market share. The global medical devices market is projected to reach $600 billion by 2026, with a CAGR of 5.4%.
Kilit Müşteriler
- Hospitals and clinics
- Healthcare providers
- Surgeons and interventional cardiologists
- Patients requiring medical device implants and therapies
- Distributors and sales representatives
Finansallar
Grafik & Bilgi
MicroPort Scientific Corporation (MCRPF) hisse senedi fiyatı: Price data unavailable
Son Haberler
MCRPF için son haber bulunmamaktadır.
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
MCRPF için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
MCRPF için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, MCRPF'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Yönetim: Zhaohua Chang
CEO
Zhaohua Chang is the Chief Executive Officer of MicroPort Scientific Corporation. His background includes extensive experience in the medical device industry, with a focus on strategic planning, business development, and operational management. He has been instrumental in driving the company's growth and expansion into new markets. His leadership is focused on innovation and globalization.
Sicil: Under Zhaohua Chang's leadership, MicroPort Scientific Corporation has expanded its product portfolio and strengthened its presence in key markets. He has overseen the development and commercialization of innovative medical devices, including surgical robots and advanced cardiovascular solutions. He is managing 6347 employees.
MCRPF OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of the OTC market, indicating that MicroPort Scientific Corporation may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to the same rigorous listing standards and regulatory oversight.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited financial disclosure increases information asymmetry and the risk of fraud.
- Lower liquidity can lead to difficulty in buying or selling shares.
- Wider bid-ask spreads can result in higher transaction costs.
- Less regulatory oversight increases the risk of mismanagement and corporate governance issues.
- Higher price volatility can lead to significant losses.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Check for any regulatory actions or legal disputes.
- Monitor trading volume and bid-ask spreads.
- Consult with a financial advisor.
- Established presence in the medical device industry.
- Global operations and distribution network.
- Diverse product portfolio across multiple therapeutic areas.
- Focus on innovation and research and development.
- Experienced management team.
MCRPF Hakkında Sıkça Sorulan Sorular
MCRPF için değerlendirilmesi gereken temel faktörler nelerdir?
MicroPort Scientific Corporation (MCRPF) şu anda yapay zeka skoru 59/100, orta puanı gösteriyor. Temel güçlü yan: Diverse product portfolio across multiple medical device segments.. İzlenmesi gereken birincil risk: Potential: Intense competition from established medical device companies.. Bu bir finansal tavsiye değildir.
MCRPF MoonshotScore'u nedir?
MCRPF şu anda MoonshotScore'da 59/100 (Derece C) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
MCRPF verileri ne sıklıkla güncellenir?
MCRPF fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler MCRPF hakkında ne diyor?
MCRPF için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
MCRPF'a yatırım yapmanın riskleri nelerdir?
MCRPF için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Intense competition from established medical device companies.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
MCRPF'ın P/E oranı nedir?
MCRPF için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için MCRPF'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
MCRPF aşırı değerli mi, yoksa düşük değerli mi?
MicroPort Scientific Corporation (MCRPF)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
MCRPF'ın temettü verimi nedir?
MicroPort Scientific Corporation (MCRPF) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Limited analyst coverage due to OTC listing.
- Financial data based on available public information.